IP Library › Granted Patent US 12,595,484
Granted Patent B2
US 12,595,484 · App. 18/933,819 · Granted Apr 7, 2026

Composition for regulating production of interfering ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/1136C12N15/86C12N2310/141C12N2750/14141
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,595,484
App. No.
18/933,819
Granted
Apr 7, 2026
Kind
B2
Abstract

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a cytokine or other mediator molecule of an inflammatory response.

Claims (4)

1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 7.

2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.

3 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 17.

4 . The composition of claim 3 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072083/0016 →
Continuity (2)
Division 18517808 · Nov 22, 2023
Related Publication 20250163463A1 · May 22, 2025
References Cited (58)
US 11085055B2 · Mallol et al. · 2021 [cited by applicant]
US 11162102B2 · Minshull · 2021 [cited by applicant]
US 11530423B1 · Thompson · 2022 [cited by applicant]
US 11873505B2 · Thompson · 2024 [cited by applicant]
US 12018274B2 · Thompson · 2024 [cited by applicant]
US 12134770B1 · Thompson · 2024 [cited by applicant]
US 12195747B1 · Thompson · 2025 [cited by applicant]
US 20240026377A1 · Thompson · 2024 [cited by applicant]
US 20240366789A1 · Fu et al. · 2024 [cited by applicant]
CA 2721333A1 · 2009 [cited by applicant]
CN 108998451A · 2018 [cited by applicant]
[cited by examiner]
[cited by examiner]
[cited by examiner]
O'Brien et al., Aug. 3, 2018, “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation”, Front Endocrinol (Lausanne), 9:402, p. 1-12 (Year: 2018). [cited by examiner]
Agarwal et al., 2015, “Predicting effective microRNA target sites in mammalian mRNAs” eLife, 4: e05005, Release 8.0, Sep. 2021 (Year: 2015). [cited by examiner]
Li et al., Jan. 10, 2022, “miR-190a-5p Partially Represses the Abnormal Electrical Activity of SCN3B in Cardiac Arrhythmias by Downregulation of IL-2″ Frontiers in Cardiovascular Medicine”, vol. 8, Article 795675 (Year:… [cited by examiner]
[cited by examiner]
[cited by examiner]
Xu et al., 2010, “MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines”Cancer Cell International, 10:15, p. 1-7 (Year: 2010). [cited by examiner]
Momin et al., 2021, Cells, 10, 3097, p. 1-21 (Year: 2021). [cited by examiner]
Zhang et al., “The Risks of miRNA Therapeutics: In a Drug Target Perspective,” Drug Design, Development and Therapy 15: 721-733 (Year: 2021). [cited by applicant]
Zhang et al., “Cytokines, Inflammation and Pain”, Int. Anesthesiol. Clin. 54(2): 27-37 (Year 2007). [cited by applicant]
WIPO translation of CN 108998451A (Year 2018). [cited by applicant]
Asirvatham et al. “miRNA regulation of cytokine genes”, Cytokine 45(2): 58-69 (Year: 2009). [cited by applicant]
Fiona T van den Berg, et al., Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016). [cited by applicant]
Denzler R et al., Mol Cell. Nov. 3, 2016; 64(3):565-579 (Year: 2016). [cited by applicant]
Gorski, S. Vogel, J. & Doudna, J., Nat Rev Mol Cell Biol 18, 215-228 (2017) (Year: 2017). [cited by applicant]
GenBank IL-1b mRNA Sequence Nov. 2023 version (Year: 2023). [cited by applicant]
Nature (2010.Gene Expression. Scitable, Available online at Nature.com. Accessed Dec. 23, 2024) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (Year: 2010). [cited by applicant]
Tritschler et al., 2019, Concepts and limitation for learning developmental trajectories from single cell genomics. Devemopment 146: dev170506) (Year: 2019). [cited by applicant]
GenBank IL-1b gene Sequence Nov. 2023 version (Year: 2023). [cited by applicant]
Shang et al. Nature Reviews Genetics, vol. 24, p. 817; Jun. 28, 2023 (Year: 2023). [cited by applicant]
Depieri et al., European Journal of Pharmaceutics and Biopharmaceitics, vol. 105, p. 50-58, Aug. 2016 (Year 2016). [cited by applicant]
Yuan et al., Molecular Medicine Reports, vol. 16, p. 2529-2537; Jul. 6, 2017 (Year: 2017). [cited by applicant]
Teoh, et al., Leukemia Research, vol. 40, p. 44-53; Jan. 2016 (Year: 2016). [cited by applicant]
[cited by applicant]
[cited by applicant]
Fayyad-Kazan et al., 2014, “Downregulation of microRNA-24 and -181 parallels the upregulation of IFN-y secreted by activated human CD4 lymphocytes” Huan Immunology, 75 (2014), p. 677-685 (Year: 2014). [cited by applicant]
GenBank1, NG_033019.1, [cited by applicant]
Lam et al. “siRNA Versus miRNA as Therapeutics for Gene Silencing”. Molecular Therapy. Nucleic Acids. vol. 4 (2015) pp. e252-e252 (Year: 2015). [cited by applicant]
Ying et al. “The MicroRNA (miRNA): OVerview of the RNA Genes that Modulate Gene Function”. Mol. Biotechnol. (2008) 38:257-268. (Year: 2008). [cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112. [cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848. [cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166. [cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253. [cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494. [cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016. [cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery.” Nature reviews Drug discovery 18.5 (2019): 358-378. [cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675. [cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023). [cited by applicant]
GenBank EGFR Sequence (2023). [cited by applicant]
GenBank EGF Sequence (2023). [cited by applicant]
NCBI search results for SEQ ID No. 5 (2024). [cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024). [cited by applicant]
GenBank FLT3 Sequence (2024). [cited by applicant]